The oncologist · 2025
Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Xi-Lin, Wei Li-Chun, He Jian-Li, Wang Tie-Jun, Ran Li, Zou Li-Juan, Sun Xiao-Ge, Li Xiao-Mei, Liu Zi, Shi Yong-Gang, Li Sha, Zhao Feng-Ju, Gao Kun, Zhong Wei, Cheng Guang-Hui, Gao Ya-Li, Sun Bao-Sheng, Yan Jun-Fang, Zhang Fu-Quan
Аннотация
OBJECTIVE: To compare the survival difference between 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer (CC) patients with unilateral parametrial invasion (UL) and bilateral parametrial invasion (BL) disease, and explore the significant role of parametrial invasion (PI) in prognosis prediction.
METHODS: A total of 506 stage IIB CC patients were identified from the multi-center study, and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between 2 groups before and after propensity scoring matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide a better understanding toward the findings from the RF model.
RESULTS: Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before (BL: 61.7% [95% CI: 57.0%-66.4%]; UL: 84.8% [95% CI: 82.4%-87.2%]; HR = 2.83, 95% CI: 1.90-4.20, P < 0.001) or after PSM (BL: 61.3% [95% CI: 56.6%-66.0%]; UL: 81.2% [95% CI: 77.3%-85.1%]; HR = 2.51, 95% CI: 1.56-4.04, P < 0.001). Similar findings could also be observed in terms of progression-free survival (PFS). The presence of VI didn't significantly impair the survival probability, whether in the UL or BL group (all P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (area under the receiver operating characteristic curve [AUC] = 0.893; 95% CI: 0.874-0.912) and validation cohort (AUC = 0.879; 95% CI: 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.
CONCLUSION: Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had a worse prognosis than those with UL disease, and PI was the most significant feature in prognosis prediction for these patients.
METHODS: A total of 506 stage IIB CC patients were identified from the multi-center study, and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between 2 groups before and after propensity scoring matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide a better understanding toward the findings from the RF model.
RESULTS: Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before (BL: 61.7% [95% CI: 57.0%-66.4%]; UL: 84.8% [95% CI: 82.4%-87.2%]; HR = 2.83, 95% CI: 1.90-4.20, P < 0.001) or after PSM (BL: 61.3% [95% CI: 56.6%-66.0%]; UL: 81.2% [95% CI: 77.3%-85.1%]; HR = 2.51, 95% CI: 1.56-4.04, P < 0.001). Similar findings could also be observed in terms of progression-free survival (PFS). The presence of VI didn't significantly impair the survival probability, whether in the UL or BL group (all P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (area under the receiver operating characteristic curve [AUC] = 0.893; 95% CI: 0.874-0.912) and validation cohort (AUC = 0.879; 95% CI: 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.
CONCLUSION: Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had a worse prognosis than those with UL disease, and PI was the most significant feature in prognosis prediction for these patients.